文献速递妇科

葡萄牙多中心研究:IOTA方法分类附件肿物的前瞻性外部验证及良性描述符与ADNEX模型两步策略的回顾性评估

Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX model: Portuguese multicenter study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-09-04

该研究在葡萄牙三个三级转诊中心前瞻性纳入571例附件肿瘤患者,外部验证IOTA简单规则、LR2和ADNEX模型,并与主观评估和RMI比较;同时回顾性验证良性简单描述符(MBDs)联合ADNEX模型的两步策略。结果显示IOTA方法表现良好,优于RMI,ADNEX模型准确度最高,但鉴别恶性亚型受样本量和亚型患病率差异限制;MBDs可可靠识别良性疾病,两步策略适合日常临床实践。

要点

  • IOTA方法在葡萄牙人群中表现良好至优秀,优于RMI。
  • ADNEX模型准确度最高,但鉴别恶性亚型受样本量和亚型患病率差异限制。
  • MBDs可可靠识别良性疾病,两步策略适合日常临床实践。

核心结论

  • IOTA方法在葡萄牙人群中表现良好至优秀,优于RMI。
  • ADNEX模型在准确度方面优于其他方法,但其鉴别恶性亚型的能力解读受样本量和肿瘤亚型患病率巨大差异的限制。
  • IOTA MBDs可可靠识别良性疾病。
  • 由MBDs应用后对不适用者再应用ADNEX模型组成的两步策略适合日常临床实践,避免了在所有患者中计算恶性肿瘤风险。

研究设计与样本

  • 前瞻性多中心诊断准确性研究,于2016年1月至2021年12月在葡萄牙里斯本三个三级转诊中心连续纳入超声诊断至少一个附件肿瘤并接受手术的患者。
  • 所有超声评估由具有IOTA认证的II级或III级超声医师完成。
  • 参考标准为组织病理学诊断。
  • 第二阶段回顾性使用两步策略(MBDs + ADNEX)对所有附件肿瘤进行分类。

主要发现

  • 共纳入571例患者,其中428例为良性疾病,143例为恶性疾病(恶性肿瘤患病率25.0%),包括42例交界性卵巢肿瘤、93例原发性浸润性附件癌和8例附件转移性肿瘤。
  • 主观评估鉴别良恶性的总体敏感度为97.9%,特异度为83.6%。
  • RMI特异度高(95.6%)但敏感度极低(58.7%),AUC为0.913。
  • IOTA简单规则适用于80.0%的患者,敏感度为94.8%,特异度为98.6%。
  • IOTA LR2在恶性肿瘤风险截断值10%时,敏感度为84.6%,特异度为86.9%,AUC为0.939。

关键数值与推荐

  • IOTA简单规则适用于80.0%的患者,敏感度94.8%,特异度98.6%。
  • IOTA LR2在恶性肿瘤风险截断值10%时,敏感度84.6%,特异度86.9%,AUC 0.939。
  • ADNEX模型在恶性肿瘤风险截断值10%时,联合CA 125的敏感度95.8%、特异度82.5%、AUC 0.962;不联合CA 125的敏感度98.6%、特异度79.7%、AUC 0.960。
  • MBDs适用于26.3%(150/571)的病例,其中无一例为恶性。
  • 两步策略(MBDs + ADNEX)联合与不联合CA 125的AUC分别为0.964与0.961。

临床怎么用

  • 作者认为,由MBDs应用后对不适用者再应用ADNEX模型组成的两步策略适合日常临床实践,避免了在所有患者中计算恶性肿瘤风险。
  • 作者认为,IOTA MBDs可可靠识别良性疾病。

局限性

  • ADNEX模型鉴别恶性亚型的能力解读受样本量和肿瘤亚型患病率巨大差异的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To externally and prospectively validate the International Ovarian Tumor Analysis (IOTA) Simple Rules (SRs), Logistic Regression model 2 (LR2) and Assessment of Different NEoplasias in the adneXa (ADNEX) model in a Portuguese population, comparing these approaches with subjective assessment and the risk-of-malignancy index (RMI), as well as with each other. This study also aimed to retrospectively validate the IOTA two-step strategy, using modified benign simple descriptors (MBDs) followed by the ADNEX model in cases in which MBDs were not applicable. METHODS: This was a prospective multicenter diagnostic accuracy study conducted between January 2016 and December 2021 of consecutive patients with an ultrasound diagnosis of at least one adnexal tumor, who underwent surgery at one of three tertiary referral centers in Lisbon, Portugal. All ultrasound assessments were performed by Level-II or -III sonologists with IOTA certification. Patient clinical data and serum CA 125 levels were collected from hospital databases. Each adnexal mass was classified as benign or malignant using subjective assessment, RMI, IOTA SRs, LR2 and the ADNEX model (with and without CA 125). The reference standard was histopathological diagnosis. In the second phase, all adnexal tumors were classified retrospectively using the two-step strategy (MBDs + ADNEX). Sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios and overall accuracy were determined for all methods. Receiver-operating-characteristics curves were constructed and corresponding areas under the curve (AUC) were determined for RMI, LR2, the ADNEX model and the two-step strategy. The ADNEX model calibration plots were constructed using locally estimated scatterplot smoothing (LOESS). RESULTS: Of the 571 patients included in the study, 428 had benign disease and 143 had malignant disease (prevalence of malignancy, 25.0%), of which 42 had borderline ovarian tumor, 93 had primary invasive adnexal cancer and eight had metastatic tumors in the adnexa. Subjective assessment had an overall sensitivity of 97.9% and a specificity of 83.6% for distinguishing between benign and malignant lesions. RMI showed high specificity (95.6%) but very low sensitivity (58.7%), with an AUC of 0.913. The IOTA SRs were applicable in 80.0% of patients, with a sensitivity of 94.8% and specificity of 98.6%. The IOTA LR2 had a sensitivity of 84.6%, specificity of 86.9% and an AUC of 0.939, at a malignancy risk cut-off of 10%. At the same cut-off, the sensitivity, specificity and AUC for the ADNEX model with vs without CA 125 were 95.8% vs 98.6%, 82.5% vs 79.7% and 0.962 vs 0.960, respectively. The ADNEX model gave heterogeneous results for distinguishing between benign masses and different subtypes of malignancy, with the highest AUC (0.991) for discriminating benign masses from primary invasive adnexal cancer Stages II-IV, and the lowest AUC (0.696) for discriminating primary invasive adnexal cancer Stage I from metastatic lesion in the adnexa. The calibration plot suggested underestimation of the risk by the ADNEX model compared with the observed proportion of malignancy. The MBDs were applicable in 26.3% (150/571) of cases, of which none was malignant. The two-step strategy using the ADNEX model in the second step only, with and without CA 125, had AUCs of 0.964 and 0.961, respectively, which was similar to applying the ADNEX model in all patients. CONCLUSIONS: The IOTA methods showed good-to-excellent performance in the Portuguese population, outperforming RMI. The ADNEX model was superior to other methods in terms of accuracy, but interpretation of its ability to distinguish between malignant subtypes was limited by sample size and large differences in the prevalence of tumor subtypes. The IOTA MBDs are reliable in identifying benign disease. The two-step strategy comprising application of MBDs followed by the ADNEX model if MBDs are not applicable, is suitable for daily clinical practice, circumventing the need to calculate the risk of malignancy in all patients. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Borges AL, Brito M, Ambrósio P, et al. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX model: Portuguese multicenter study. Ultrasound Obstet Gynecol. 2024. PMID: 38477149. doi:10.1002/uog.27641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。